58808
| Pregunta | Respuesta |
| list prolems w/production of theraputic mAB | 1.choice of organism 2. glycosylation 3. scale up 4. cost 5. authenticity 6. test for contamination |
| monoclonal antibodies | 1. Derived from a single B cell clone 2. Reproducible, Predictable & Potentially inexhaustible supply of Ab with exquisite specificity |
| Monoclonal antibody therapy | the use of monoclonal antibodies (or mAb) to specifically bind to target cells or proteins. This may then stimulate the patient's immune system to attack those cells. |
| Limiting factors of mAbs | 1.Acute reactions to mAbs 2. Antigenic modulation of the tumour 3. Immune response to mAbs 4. Tissue cross-reactivity with mAbs 5. Limited effector function 6. Tumour localisation 7. Tumour penetration |
| Monoclonal antibodies are used in vitro | for bone marrow purging, cell purifications |
| Monoclonal antibodies are used in vivo | tumours, preventing transplant rejection; tx of autoimmune disease, tx of infectious disease, leukaemia |
¿Quieres crear tus propias Fichas gratiscon GoConqr? Más información.